Quest Diagnostics Incorporated Q2 FY26 Results — Earnings Call Analysis
Published 29 May 2026 | Health Care Providers and Services | Market Cap: ₹21.7K Cr
- Q1 2026 organic volume growth was strong at 10.8%, with total volume growth at 10.9%. - Full year 2026 revenue guidance raised to $11.78 billion - $11.9 billion, a growth rate of 6.8% to 7.8%.
From Quest Diagnostics Incorporated's Q2 FY26 earnings-call transcript · updated 29 May 2026.
Price
₹196.2
Market Cap
₹21.7K Cr
P/E Ratio
21.3
Revenue Rank
Margin Rank
How does Quest Diagnostics Incorporated rank in Health Care Providers and Services?
Compare Quest Diagnostics Incorporated against every Health Care Providers and Services company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 3- →Q1 2026 organic volume growth was strong at 10.8%, with total volume growth at 10.9%.
- →Excluding Corewell and Fresenius partnerships, organic volume growth was 3.8%.
- →Fresenius and Corewell collaborations contribute approximately 7% to organic volume growth.
- →Revenue guidance for 2026 raised to $11.78B to $11.9B, reflecting 6.8% to 7.8% growth.
- →Continued strong growth expected in physician, hospital, and consumer health channels.
- →Advanced diagnostics and consumer health segments show strong double-digit growth.
- →Partnerships and collaborations, including with wellness and wearable companies, expected to further accelerate growth.
- →Higher test per requisition driven by advanced tests and screening options supports revenue per requisition growth.
- →Corewell and Fresenius expected to add approximately $330-$350 million combined revenue growth in 2026.
- →Seasonality: Just over 49% of revenue and EPS in the first half, slightly over 50% in the second half, with continued strong organic utilization.
📈 Profitability & Margins
Rank 3- →Full year 2026 revenue guidance raised to $11.78 billion - $11.9 billion, a growth rate of 6.8% to 7.8%.
- →Reported EPS guidance updated to $9.58 - $9.78.
- →Adjusted EPS guidance raised to $10.63 - $10.83, reflecting strong first quarter momentum.
- →Operating margin expected to expand versus prior year.
- →Productivity gains from automation and AI to support earnings growth.
- →Project Nova investments expected to cause $0.25 EPS dilution for 2026, with expenses ramping more in second half.
- →Margin profile improvements anticipated, especially from partnerships (e.g., Fresenius) as businesses ramp.
- →EPS improvement expected over course of the year but early to quantify dilution or improvement specifics.
- →No M&A contribution included in 2026 guidance; M&A pipeline remains active but cautious.
- →Fuel cost inflation embedded in guidance; estimated $0.05 to $0.07 EPS impact.
🏗️ Capital Expenditure Plans
Yes- →$550 million capital expenditures forecasted for 2026, consistent with 2025 levels (Page 3).
- →Significant portion of capital investments allocated to esoteric labs for capacity upgrades to support advanced diagnostics growth (Page 11).
- →Continued investments in advanced diagnostics, including brain health biomarkers (AB 42/40, ApoE, NFL, p-tau181/217), cardiometabolic testing, and oncology partnerships (Page 11).
- →Ongoing support for Haystack cancer detection test, including commercial ramp and reimbursement efforts (Page 11-12).
- →Scaling planning and design for Project Nova, a multi-year initiative to transform order-to-cash processes with first wave implementation expected in fall 2027 (Page 3, 6).
- →No specific M&A contribution included in 2026 guidance, but M&A funnel remains active with ongoing evaluations of health system outreach deals (Page 12).
💰 Fundraising & Capital Structure
No information- →The transcript does not mention any current or planned fundraising through debt or equity.
- →2026 guidance includes expectations for cash from operations (~$1.75 billion), capital expenditures (~$550 million), and consistent share count and interest expense compared to 2025.
- →There is no indication of new debt issuance or equity offerings within the provided pages.
- →The company states that 2026 revenue guidance does not include any contribution from prospective M&A, suggesting a cautious approach to growth but no explicit fundraising plans.
- →Overall, no explicit plans for new fundraising via debt or equity are disclosed in the discussed call.
📋 Order Book & Pipeline
YesKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
Others in Health Care Providers and Services this season
- BrightSpring Health Services, Inc. (Q2 FY26)
BrightSpring Health Services, Inc. Q2 FY26 quarterly results analysis. Pharmacy Solutions expected to see balanced sequential revenue and EBITDA growth througho
- DaVita Inc. (Q2 FY26)
DaVita Inc. Q2 FY26 quarterly results analysis. Treatment volume guidance raised from flat to 25-50 basis points growth for 2026, driven by better underlying pe
- Tenet Healthcare Corporation (Q2 FY26)
Tenet Healthcare Corporation Q2 FY26 quarterly results analysis. Hospital segment expects a 10% normalized year-over-year adjusted EBITDA growth in 2026, suppor
- Guardant Health, Inc. (Q2 FY26)
Guardant Health, Inc. Q2 FY26 quarterly results analysis. Sales team started this year with ~300 reps; incremental gross profit will be reinvested in expanding
Frequently Asked Questions
What were Quest Diagnostics Incorporated Q2 FY26 results?
- Q1 2026 organic volume growth was strong at 10.8%, with total volume growth at 10.9%. - Full year 2026 revenue guidance raised to $11.78 billion - $11.9 billion, a growth rate of 6.8% to 7.8%.
What is Quest Diagnostics Incorporated share price analysis?
Quest Diagnostics Incorporated currently shows a below-average growth signal. The stock trades at a P/E of 21.3 with a market cap of $21,719. Investors should review the full earnings analysis for detailed insights.
Is Quest Diagnostics Incorporated planning capital expenditure?
- $550 million capital expenditures forecasted for 2026, consistent with 2025 levels (Page 3).
Keep Quest Diagnostics Incorporated on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.